Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Exjade-Early-Trial

This study has been terminated.
(Insufficient patient recruitment (only 2 patients))
Sponsor:
Collaborator:
Novartis Pharmaceuticals
Information provided by (Responsible Party):
University of Erlangen-Nürnberg Medical School
ClinicalTrials.gov Identifier:
NCT01058369
First received: January 27, 2010
Last updated: January 7, 2013
Last verified: January 2013
  Purpose

Study outline: Deferasirox (Exjade®) is regularly used in severe iron overload in order to avoid organ damage of liver, heart and other organs. It has been proposed, that iron overload may not only impose damage to other organs but also to the bone marrow and thus worsen hematopoietic insufficiency in patients with MDS. Patients presenting with low or INT-1 risk MDS with only mild iron overload will be treated with deferasirox in this study. It will be analyzed if hematological improvement can be observed during this treatment.


Condition Intervention Phase
Myelodysplastic Syndromes
Drug: Deferasirox (Novartis Pharma)
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Early Treatment With Deferasirox (Exjade®) in Low Risk MDS - a Prospective Multicentre Single-arm Single-stage Phase II Study -

Resource links provided by NLM:


Further study details as provided by University of Erlangen-Nürnberg Medical School:

Primary Outcome Measures:
  • Fraction of patients with hematologic improvement according to modified IWG criteria (reduction of transfusions and/or increase in Hb, improvement of neutropenia and thrombocytopenia) [ Time Frame: within two years ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Evaluate the safety and tolerability profile of deferasirox in MDS patients [ Time Frame: within two years ] [ Designated as safety issue: Yes ]
  • Effectiveness of iron depletion [ Time Frame: within two years ] [ Designated as safety issue: No ]
  • Correlation between hematological improvement and effectiveness of iron depletion [ Time Frame: two years ] [ Designated as safety issue: No ]
  • Development of bone marrow morphology [ Time Frame: two years ] [ Designated as safety issue: No ]
  • Correlation between hematological improvement and pretreatment parameters. Extension of this analysis to MDS patients on deferasirox within the licensed indication (more severe iron overload) [ Time Frame: two years ] [ Designated as safety issue: No ]
  • overall survival [ Time Frame: within two years ] [ Designated as safety issue: No ]
  • AML-free survival [ Time Frame: within two years ] [ Designated as safety issue: No ]

Enrollment: 2
Study Start Date: April 2010
Estimated Study Completion Date: January 2013
Estimated Primary Completion Date: January 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Deferasirox Drug: Deferasirox (Novartis Pharma)
Treatment period 102 weeks. Starting dose 10mg/kg/day. Up to 30/mg/kg according to dose adjustment table as specified in the protocol
Other Name: Exjade(R)

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • MDS of subtype RA, RARS, RCMD, RCMD-RS (i.e. lower risk)
  • RAEB I allowed, if clinically stable for > 3 months
  • 5q-minus syndrome allowed, if lenalidomide unsuccessful or unavailable at the time of inclusion
  • IPSS score < intermediate-1
  • transfusion dependent or Hb < 10,5 g/dl
  • History of less than 20 units of red blood cell transfusions or 100mL/kg of prepacked red blood cells (PRBCs), except for transfusions for acute bleeding
  • Serum ferritin > 300 µg/l and < 1500 μg/l. This level should have been verified at least at two occasions within 3 months. Samples must be obtained in the absence of concomitant severe infection
  • no indication for EPO (due to high endogenous EPO levels) or EPO without benefit in the past
  • no indication and/or no plans for cytostatic drugs
  • no previous exposure to cytostatic drugs, thalidomide, lenalidomide, G-CSF or EPO or exposure to any of these drugs has been terminated since > 8 weeks (4 weeks for G-CSF).
  • no indication and/or no plans for stem cell transplantation
  • stable or worsening cytopenia during the past 8 weeks. If in doubt, extend screening period to >= 8 weeks
  • Patients of either gender and age > 18 years
  • Life expectancy > 12 months
  • Females of childbearing potential must use double-barrier contraception (for example orale contraception and condom).
  • Mental ability of the patient to understand explications concerning the study and to understand and follow instructions of the investigating physician
  • Written informed consent by the patient

Exclusion Criteria:

  • Treatment with deferasirox or other chelation therapy for periods > 4 weeks before study start
  • Patients with intolerance to Deferasirox
  • Patients with a concomitant second malignant disease, possibly interfering with life expectancy
  • Patients with mean levels of alanine aminotransferase (ALT) > 5x ULN
  • Patients with uncontrolled systemic hypertension
  • Patients with serum creatinine > 1.5x the upper limit of normal (ULN) or a creatinine clearance < 60 ml/min according to the MDRD formula (Levey 2005)
  • History of nephrotic syndrome
  • Systemic diseases (cardiovascular, renal, hepatic, etc.) which would prevent the patient from undergoing study treatment
  • Patients with psychiatric or addictive disorders which prevent them from giving their informed consent or undergoing study treatment
  • Patients treated with systemic investigational drugs within the past 4 weeks or topical investigational drug within the past 7 days
  • Any other surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of any drug. The investigator should be guided by evidence of any of the following:
  • history of inflammatory bowel syndrome, gastritis, ulcers, gastrointestinal or rectal bleeding;
  • history of major gastrointestinal tract surgery such as gastrectomy, gastroenterostomy, or bowel resection;
  • history of pancreatic injury or pancreatitis; indications of impaired pancreatic function/injury as indicated by abnormal lipase or amylase;
  • history of urinary obstruction or difficulty in voiding
  • History of non-compliance to medical regimens and patients who are considered potentially unreliable and/or not cooperative
  • History of drug or alcohol abuse within the 12 months prior to dosing or evidence of such abuse as indicated by laboratory assays conducted during the screening period
  • Patients with active uncontrolled infectious disease
  • Pregnancy or breast feeding
  • QT > 470 msec on screening ECG
  • Patients with a history of Torsades de Pointes
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01058369

Locations
Germany
Medizinische Klinik 5, Universitätsklinikum Erlangen
Erlangen, Bavaria, Germany, 91054
Sponsors and Collaborators
University of Erlangen-Nürnberg Medical School
Novartis Pharmaceuticals
Investigators
Study Chair: Stefan Krause, Prof. Dr. Medizinische Klinik 5, Universitätsklinikum Erlangen
  More Information

No publications provided

Responsible Party: University of Erlangen-Nürnberg Medical School
ClinicalTrials.gov Identifier: NCT01058369     History of Changes
Other Study ID Numbers: CICL670ADE06T
Study First Received: January 27, 2010
Last Updated: January 7, 2013
Health Authority: Germany: Federal Institute for Drugs and Medical Devices

Additional relevant MeSH terms:
Myelodysplastic Syndromes
Preleukemia
Bone Marrow Diseases
Hematologic Diseases
Neoplasms
Precancerous Conditions
Deferasirox
Chelating Agents
Iron Chelating Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Sequestering Agents

ClinicalTrials.gov processed this record on November 20, 2014